使用尼马瑞韦/利托那韦延长疗程治疗 B 细胞急性淋巴细胞白血病患者的持续性冠状病毒病 2019 (COVID-19)：病例报告。
Treatment of persistent coronavirus disease 2019 (COVID-19) in a B cell acute lymphoblastic leukemia patient with using nirmatrelvir/ritonavir extended course: A case report.
发表日期：2024 Aug 24
作者：
Hassan Almarhabi, Aisha Alharbi, Mai Alalawi, Mohamed Firoze Ahamed, Ihab El-Hemaidi, Nader Damfu
来源：
Journal of Infection and Public Health
摘要：
血液恶性肿瘤患者持续感染 2019 冠状病毒病 (COVID-19) 的风险增加，这是一种独特的临床病症，最佳治疗方法尚不清楚。在此，我们报告一例急性淋巴细胞白血病 (ALL) 患者的持续性 COVID-19 病例，该患者对延长疗程 nirmatrelvir/ritonavir 成功做出反应。版权所有 © 2024 作者。由爱思唯尔有限公司出版。保留所有权利。
Patients with hematological malignancies are at increased risk of persistent coronavirus disease 2019 (COVID-19) infection, a unique clinical condition, for which the optimal treatment is unknown. Here we report a case of persistent COVID-19 in acute lymphoblastic leukemia (ALL) patient who successfully responded to extended course nirmatrelvir/ritonavir.Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.